Key Highlights
- Aclaris Therapeutics (NASDAQ:ACRS) fell 8.04% on November 16, 2026 after its Phase 2 ADMIRATION trial of bosakitug in atopic dermatitis failed.
- The anti-TSLP antibody did not meet the primary endpoint, the relative change in eczema severity scores at week 24, or any secondary endpoints.
- The drug showed robust target engagement and was generally well tolerated, but that did not translate into clinical benefit.
- The company is moving resources to modzatinib, which entered a Phase 2b trial in lichen planus, and to bispecific candidate ATI-052.
What the ADMIRATION Trial Showed
Aclaris Therapeutics (NASDAQ:ACRS) tested bosakitug, a humanized antibody that blocks thymic stromal lymphopoietin, or TSLP, a signalling protein released by skin and airway cells that helps trigger allergic inflammation. The ADMIRATION trial enrolled patients with moderate-to-severe atopic dermatitis, the most common form of eczema. The primary endpoint was the relative change in the Eczema Area and Severity index from baseline at week 24, a standard measure that regulators accept. Bosakitug did not achieve that endpoint and also failed every secondary endpoint. The company highlighted that pharmacodynamic results showed robust engagement with TSLP and a reduction in markers of Th1, Th2 and Th17 inflammatory pathways, and that the drug was generally well tolerated. Those findings indicate the antibody did what it was designed to do biologically, yet patients' skin did not improve enough compared with placebo. The release did not provide detailed efficacy numbers or patient counts. The result adds to a mixed record for TSLP as a target in skin disease, even though the pathway has produced an approved therapy in severe asthma.
Why the Decline Was Limited
A clean miss in a lead program often produces a far steeper fall, so the 8.04% decline suggests investors had placed modest expectations on bosakitug in eczema. Aclaris has positioned itself as a company with several shots on goal in immunology, and it used the same morning to start a Phase 2b trial of modzatinib, an oral drug that blocks the ITK and JAK3 enzymes, in lichen planus, an inflammatory condition of the skin and mouth. The company also said it has completed preclinical safety studies for ATI-9494, an oral ITK inhibitor, and expects to file an investigational new drug application this quarter. In addition, a Phase 2b trial of ATI-052, a bispecific antibody that targets both TSLP and the IL-4 receptor, in eosinophilic esophagitis is planned to start in the first quarter of 2027. The session itself was hostile for risk assets, with the Nasdaq Composite down 2.49%, which means part of the move reflected broad selling rather than the trial alone.
Risks and What to Watch
The failure raises questions about whether TSLP blockade alone is sufficient in eczema, which may weigh on how investors value ATI-052, even though that candidate adds a second, clinically validated mechanism. For shareholders of Aclaris Therapeutics (NASDAQ:ACRS), the near-term focus shifts to execution on the modzatinib trial, the timing of the ATI-9494 filing and the company's cash runway, which was not updated alongside the data. Clinical-stage companies that suffer setbacks often face pressure to cut costs or raise capital, and any Equity raise at depressed prices would dilute existing holders. Competition in immunology is intense, with large companies Marketing effective injectable and oral treatments for eczema and related conditions, so differentiation will be essential for every remaining program. Full data from ADMIRATION, if presented at a medical meeting, could show whether any patient subgroup benefited and whether the program has a path forward in other diseases.
Where Things Stand
Aclaris's bosakitug failed its Phase 2 eczema trial despite strong target engagement, and the stock fell 8.04% in a weak market. The company is redirecting attention to modzatinib, ATI-9494 and the bispecific ATI-052. Pipeline execution and the cash position are the factors to watch.

_11_17_2026_18_52_19_451299.jpg)




Please wait processing your request...